SLSHIGH SIGNALOPPORTUNITY10-K

SLS achieved breakthrough clinical milestones with its Phase 2 AML trial meeting all primary endpoints and receiving FDA guidance to advance to first-line therapy, while significantly improving its financial position.

The company's SLS009 demonstrated strong efficacy with response rates substantially exceeding pre-specified thresholds across multiple patient cohorts, positioning it for potential approval in acute myeloid leukemia treatment. The FDA's guidance to advance into first-line therapy represents a major regulatory validation and expands the commercial opportunity beyond relapsed/refractory patients to the much larger newly-diagnosed AML market.

Comparing 2026-03-19 vs 2025-03-20View on EDGAR →
FINANCIAL ANALYSIS

SLS shows a substantially improved financial profile with operating cash flow improving to -$28.4M from -$35.4M despite R&D expenses growing meaningfully to support advancing clinical programs. The company reduced current liabilities by 26% and total liabilities by 25% while accounts receivable declined by half, indicating improved working capital management. However, total debt increased by 35% to $11.0M, likely reflecting financing to support the expanded clinical development following positive trial results.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-96.1%
$153K$6K

Capex reduced 96.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

R&D Expense
P&L
+68.9%
$9.3M$15.7M

R&D investment increased 68.9% — signals commitment to future product development, though near-term margin impact.

Accounts Receivable
Balance Sheet
-50.1%
$3.7M$1.8M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Total Debt
Balance Sheet
+34.6%
$8.2M$11.0M

Debt increased 34.6% — substantial leverage increase; assess whether deployed for growth or covering losses.

Current Liabilities
Balance Sheet
-26.2%
$9.5M$7.0M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-25%
$10.0M$7.5M

Liabilities reduced 25% — deleveraging improves balance sheet strength and financial flexibility.

Operating Cash Flow
Cash Flow
+19.8%
-$35.4M-$28.4M

Operating cash flow grew 19.8% — strong conversion of earnings to cash, healthy business fundamentals.

Net Income
P&L
+13%
-$30.9M-$26.9M

Net income grew 13% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+10.3%
-$31.5M-$28.3M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

LANGUAGE CHANGES
NEW — 2026-03-19
PRIOR — 2025-03-20
ADDED
In December 2025, we announced that our contract research organization informed us that the pooled number of events was 72 as of December 26, 2025.
We remain blinded to all efficacy and survival data outcomes and, as no outcomes analyses were performed and no statistical penalty has been incurred, this one-time update on the aggregate number of events does not impact future statistical analyses.
GPS was granted Orphan Drug Designations, or ODD, from the FDA, as well as orphan medicines designations from the European Medicines Agency, or EMA, in AML, malignant pleural mesothelioma, or MPM, and multiple myeloma, or MM, as well as Fast Track designations for AML, MPM, and MM from the FDA.
In December 2024, we announced positive data from the first 3 cohorts in the Phase 2a trial.
In July 2025, we announced that the Phase 2 trial of SLS009 in r/r AML met all primary endpoints and received FDA guidance to advance into a first-line therapy study.
+7 more — sign up free →
REMOVED
In December 2023, we announced that we had commenced a binding arbitration proceeding against 3D Medicines to resolve a dispute regarding, among other things, the trigger and payment of relevant milestone payments due to us under the 3D Medicines Agreement.
In addition to safety and tolerability of SLS009 in combination with aza/ven, the efficacy endpoints are complete response composite rate and duration of response.
Additional endpoints include event free survival, overall survival, and pharmacokinetic and pharmacodynamic assessments.
In the fourth quarter of 2023, we completed enrollment in the 45 mg (safety) dose cohort in the Phase 2a study and reported positive initial topline data.
At that time, we also commenced enrollment in the 60 mg dose cohort with patients randomized to one of two groups, 60 mg fixed dose once weekly or 30 mg fixed twice weekly.
+7 more — sign up free →
MORE OPPORTUNITY SIGNALS
ABTHIGHAbbott announced a major strategic acquisition of Exact Sciences Corporation to ...
2026-02-20
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →